Shots:BI & Tessellate Bio have entered into a research collaboration & global license agreement to develop oral therapies for ALT-positive tumorsAs per the terms, Tessellate Bio will receive near term payments incl. an upfront license fee, research funding & technical milestones along with downstream success-based milestones, making it an aggregate of ~$573M (~€500M)…
